Teva Pharmaceutical Industries (NYSE:TEVA) Shares Down 5.3%

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) shares dropped 5.3% during trading on Friday . The company traded as low as $13.13 and last traded at $13.14. Approximately 3,490,392 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 10,592,093 shares. The stock had previously closed at $13.87.

Analysts Set New Price Targets

TEVA has been the subject of a number of analyst reports. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price target for the company in a report on Friday, March 8th. HSBC initiated coverage on Teva Pharmaceutical Industries in a report on Monday, December 18th. They issued a "buy" rating and a $13.00 price target for the company. Barclays increased their price target on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an "overweight" rating in a report on Monday, February 5th. Jefferies Financial Group raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and increased their target price for the stock from $10.00 to $14.00 in a report on Tuesday, January 23rd. Finally, StockNews.com raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 1st. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $13.78.

Teva Pharmaceutical Industries Price Performance

The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23. The business has a 50-day moving average price of $13.39 and a two-hundred day moving average price of $11.13. The firm has a market capitalization of $14.91 billion, a price-to-earnings ratio of -28.30, a PEG ratio of 1.60 and a beta of 1.05.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.25. The business had revenue of $4.46 billion for the quarter, compared to analysts' expectations of $3.97 billion. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. As a group, research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 31,766 shares of the firm's stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CAO Amir Weiss sold 31,766 shares of the firm's stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Eric Drape sold 173,261 shares of the firm's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $13.05, for a total value of $2,261,056.05. Following the completion of the sale, the vice president now owns 1 shares in the company, valued at $13.05. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 390,738 shares of company stock worth $5,132,766. 0.62% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. Money Concepts Capital Corp bought a new position in Teva Pharmaceutical Industries during the 4th quarter valued at $25,000. Tower Research Capital LLC TRC boosted its stake in Teva Pharmaceutical Industries by 1,729.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company's stock valued at $39,000 after purchasing an additional 3,580 shares in the last quarter. US Bancorp DE boosted its stake in Teva Pharmaceutical Industries by 36.5% during the 4th quarter. US Bancorp DE now owns 3,828 shares of the company's stock valued at $40,000 after purchasing an additional 1,023 shares in the last quarter. Blue Trust Inc. boosted its stake in Teva Pharmaceutical Industries by 92.3% during the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company's stock valued at $46,000 after purchasing an additional 2,180 shares in the last quarter. Finally, Signaturefd LLC boosted its stake in shares of Teva Pharmaceutical Industries by 90.8% during the 3rd quarter. Signaturefd LLC now owns 5,032 shares of the company's stock worth $51,000 after acquiring an additional 2,394 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.